Wednesday 17th September - Main Conference Day TwoWednesday, 17 September 2025 - ET (Eastern Time, GMT-05:00)

Next-generation biologic therapies need agile platforms for flexible processes. This session will showcase AI-driven PAT/CPV solutions that simplify ML model creation, reduce the need for skilled Data Scientists, and provide automated CPV and root-cause analysis, enhancing efficiency, consistency, and compliance in the Life Science industry.

Trusted partner to biopharma innovators across China, Europe, and Asia — now expanding across the Pacific.

Founded in 2012 and headquartered in Shanghai, China, Andgel, with a 21st-century state-of-the-art manufacturing facility and international engineering standards, specializes in the design and manufacture of stainless steel bioreactor systems and integrated bioprocess solutions. The company has delivered a wide range of bioreactors, from laboratory to commercial scales, to clients across China, Europe, and Asia.

Discover how Yokogawa’s BioPilot transforms bioprocessing with seamless digital integration and intelligent automation. By unifying real-time data acquisition and advanced process control, BioPilot empowers scientists to streamline cell culture and purification workflows—enhancing reproducibility, accelerating development timelines, and enabling effective decisions in cell line, media, and process development.

• DirectedLuck® transposase integrates genes at most active genomic sites via epigenetic targeting and delivers highest pool titers with minimal selection pressure.
• Automated clone assessment enables early clone selection based on platform fit and critical product quality parameters.
• Smart automation delivers better, high quality producer clones in shortest time.

Tecan’s Te-Chrom™ and RoboColumns® enable miniaturized, automated chromatography for upstream and downstream bioprocessing. They support high-throughput resin screening and protein capture experiments with minimal sample volumes, aiding early-stage feasibility studies. We'll share case studies illustrating their role in early development research including projects involving traditional biologics and novel protein formats.

The BioSep is a fully electronic, solid-state device designed specifically for cell separation and retention in perfusion cell culture. The device offers simple installation, operation, and maintenance and provides high cell retention rates, no fouling and long, trouble free cell culture cycles. Performance will be discussed. A new single use version will be introduced.

Explore groundbreaking research, meet the poster presenters and ask your questions.

*For your poster to be entered into the poster competition, please submit your abstract by August 1, 2025 and PDF poster by August 22, 2025*

Join us to explore how Lonza’s integrated solutions, from licensing and CHO media to biologics services, streamline the path from discovery to commercialization. Learn how we support customers with end-to-end expertise, global scale, and trusted execution.

During the production of bispecific antibodies (bsAbs), issues such as proteolytic degradation or incomplete assembly can lead to the formation of undesired fragments, including Fab and Fc regions. These fragments are typically detected using analytical methods like SDS-PAGE, mass spectrometry, and Western blotting, which provide insights into the molecule’s size, structural integrity, and overall composition.

Accurate characterization of these fragments is crucial, as they may adversely affect the bsAb’s stability, binding properties, pharmacokinetics, and therapeutic performance. Moreover, the presence of such degraded or incomplete forms can increase the risk of immunogenicity. A thorough analytical approach is therefore essential—not only to ensure product quality and regulatory compliance, but also to support robust process development and reliable clinical outcomes.

Explore groundbreaking research and meet the poster presenters with your questions.

*For your poster to be entered into the poster competition, please submit your abstract by August 1, 2025 and PDF poster by August 22, 2025*